Pfizer, Samsung Biologics build on biosimilar deals now worth $897M

Pfiz­er has ex­pand­ed up­on a pair of agree­ments with Sam­sung Bi­o­log­ics to make its biosim­i­lars in a deal worth al­most $900 mil­lion.

Ac­cord­ing to a fact sheet sent to End­points News, Sam­sung Bi­o­log­ics and Pfiz­er said they in­creased one agree­ment, signed in March, to $193 mil­lion, and amend­ed a sec­ond agree­ment, an­nounced in June, to $704 mil­lion.

The com­pa­nies did not dis­close what prod­ucts Sam­sung will be man­u­fac­tur­ing, though the South Ko­re­an man­u­fac­tur­er said the deal calls for mul­ti­ple prod­ucts to be pro­duced, which is dif­fer­ent from more con­ven­tion­al con­tracts that are usu­al­ly for one prod­uct.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN